Table 2.
Association of urinary TXB2 levels with prostate cancer
| TXB2 | Odds of case status |
||
|---|---|---|---|
| Control, No. (%) | Case, No. (%) | OR (95% CI)a | |
| All cases | |||
| ≤Medianb | 500 (50.0) | 397 (41.8) | Ref |
| >Median | 499 (50.0) | 554 (58.2) | 1.24 (1.02 to 1.50) |
| African American | |||
| ≤Median | 254 (54.5) | 193 (40.6) | Ref |
| >Median | 212 (45.5) | 282 (59.4) | 1.50 (1.13 to 2.00) |
| European American | |||
| ≤Median | 246 (46.2) | 204 (42.9) | Ref |
| >Median | 287 (53.8) | 272 (57.1) | 1.07 (0.82 to 1.40) |
Unconditional logistic regression adjusted for age at study entry, body mass index (kg/m2), diabetes (no or yes), aspirin (no or yes), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes or no), self-reported race (not included in stratified analysis), and smoking history (never, former, current). CI = confidence interval; OR = odds ratio; Ref = reference.
Median cutoff point is 0.505 ng TXB2/mg creatinine.